Chronic Spontaneous Urticaria

IF 2.7 3区医学 Q2 ALLERGY

Immunology and Allergy Clinics of North America Pub Date : 2024-08-26 DOI:10.1016/j.iac.2024.07.001

引用次数: 0

慢性自发性荨麻疹：当前和新出现的生物制剂。

抗组胺难治性慢性自发性荨麻疹（CSU）的发病率高达 50%。抗免疫球蛋白 E（IgE）疗法彻底改变了 CSU 的治疗方法，但难治性病例依然存在，这表明生物制剂可以发挥作用，影响肥大细胞刺激的其他途径，而不受 FcεR1 交联的影响。本综述探讨了治疗 CSU 的抗 IgE 和 Th2 靶向疗法。此外，我们还探讨了针对肥大细胞活化替代途径的新型疗法，包括与 MAS 相关的 G 蛋白偶联受体-X2 和唾液酸结合免疫球蛋白样凝集素-6、通过布鲁顿酪氨酸激酶抑制细胞内信号传导以及通过 SCF 破坏 KIT 的活化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology and Allergy Clinics of North America 医学-过敏

CiteScore

5.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.